[Peripheral blood stem cell collection in pediatric malignancies: comparison between three mobilizing regimens].
OBJECTIVE
The optimal method for PBSC (peripheral blood stem cells) mobilization in pediatric patients is still unknown. The present study was conducted to evaluate the safety of apheresis procedures and to compare the efficacy of three methods of PBSC mobilization.


METHODS
Our study was performed on 28 pediatric patients (in three groups) with solid tumors at onset or on relapse. In two groups we tried to mobilize PBSC administering CHT (based on Carboplatin with Etoposide in the first group and Cyclophosphamide in the second group) followed by granulocyte colony stimulating factor (G-CSF); in the third group the mobilization regimen was based on G-CSF alone.


RESULTS
Forty-nine mobilizations have been performed and a median of 6.5 CD34+ cells x 10(6)/Kg were collected, with a median number of one apheresis for each patient. Using Carboplatin with G-CSF and Cyclophosphamide with G-CSF we collected respectively a median value of 6.75 and 7.3 x 10(6) CD34+ cells/kg. The mobilization method based on G-CSF alone showed to be less effective (median of 4.3 CD34+ cells x 10(6)/kg collected).


CONCLUSIONS
In our experience the mobilizing regimens based on Carboplatin or Cyclophosphamide associated with G-CSF resulted both effective and better than the one based on G-CSF alone with a scanty number of apheresis procedures.
De Pasquale
M D
MD
S.S. Oncologia Pediatrica, Policlinico Umberto I, Roma, Italy.
Cacchione
A
A
Foco
M
M
Gozzer
M
M
Libera
F
F
Soscia
F
F
Ragni
G
G
Cappelli
C
C
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000970:Antineoplastic Agents / Q000008:administration & dosage; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D001781:Blood Component Removal; D001835:Body Weight; D001859:Bone Neoplasms / Q000628:therapy; D016190:Carboplatin / Q000008:administration & dosage; D002528:Cerebellar Neoplasms / Q000628:therapy; D002648:Child; D002675:Child, Preschool; D003520:Cyclophosphamide / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods*; D006801:Humans; D007223:Infant; D008297:Male; D008527:Medulloblastoma / Q000628:therapy; D009369:Neoplasms / Q000628:therapy*; D009447:Neuroblastoma / Q000628:therapy; D012516:Osteosarcoma / Q000628:therapy; D012208:Rhabdomyosarcoma / Q000628:therapy; D012509:Sarcoma / Q000628:therapy; D012983:Soft Tissue Neoplasms / Q000628:therapy; D013234:Stem Cells; D013997:Time Factors
D000970:Antineoplastic Agents; D018906:Antineoplastic Agents, Alkylating; D000972:Antineoplastic Agents, Phytogenic; D016179:Granulocyte Colony-Stimulating Factor; D005047:Etoposide; D003520:Cyclophosphamide; D016190:Carboplatin